Dr. Adam S. Arthur Joins inTRAvent Medical as the Chief Clinical Strategy Officer to Lead Clinical Strategy and Guide Platform Development
BLUE BELL, Pa.--(BUSINESS WIRE)--inTRAvent Medical, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, proudly announces the appointment of Dr. Adam S. Arthur, MD, MPH, as Chief Clinical Strategy Officer (CCSO). In this role, Dr. Arthur will lead the company's clinical strategy for the upcoming launch of inTRAvent's platform for external ventricular drain (EVD) placement, SOLOPASS ®, while guiding the development of additional minimally invasive applications.
"Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement."
Dr. Arthur brings a wealth of experience to inTRAvent Medical, with a distinguished career in both open cerebrovascular and endovascular neurosurgery. As the James T. Robertson Endowed Professor and Chair of Neurosurgery at the University of Tennessee Health Science Center, and a practicing neurosurgeon at Semmes Murphey Clinic, he has been at the forefront of neurovascular treatment advancements. His leadership in clinical trials, including the pivotal WEB-IT, STEM, and MIND studies, underscores his commitment to advancing innovation to improve patient outcomes.
inTRAvent's FDA cleared SOLOPASS ® delivers real-time ultrasound imaging during EVD placement procedures, integrating frameless fixation with a rigid guidance system designed to support precise localization and navigation in critical-care environments.
'Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement,' Arthur said. 'Importantly, this platform also creates a pathway for minimally invasive approaches to treating intracranial hemorrhage – without the need to move critically ill patients from the ICU.'
The SOLOPASS system, designed from inception for the critical-care setting, combines 2D and 3D ultrasound imaging, AI, and trajectory guidance to provide real-time intra-procedural localization and navigation – avoiding the limitations of traditional systems, which rely on preoperative images that can become unreliable and no longer reflect actual anatomy due to brain shift or evolving pathology.
'Dr. Arthur's exceptional expertise and forward-thinking approach to neurosurgery make him an invaluable addition to our team,' said inTRAvent Medical's CEO, Adam Barner. 'His insights will help guide the continued clinical development of our SOLOPASS ® platform to address significant unmet clinical needs.'
About inTRAvent Medical Partners
inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures. Its first product, SOLOPASS®, enables simple, portable neuro-navigation using 2D and 3D ultrasound imaging, artificial intelligence, and trajectory guidance for intra-procedural localization and navigation. For more information, please visit www.inTRAventMedical.com, or find us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States. This milestone comes on the heels of Artera's recent announcement that its test is now updated with new insights to help higher-risk patients optimize treatment decisions. This advancement was supported by newly presented validation data, which was selected for Best of ASCO 2025. The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. Starting on June 4th, clinicians and patients in New York can access data-backed insights to personalize cancer treatment decisions. 'Receiving the New York lab license is a significant milestone for Artera,' said Andre Esteva, CEO and co-founder of Artera. 'Prostate cancer is one of the most common cancers, with the NY State Department of Health estimating that more than 15,000 men are diagnosed each year in New York alone. One of my founding goals was to increase access to AI-enabled precision medicine tools, and I'm proud our team has accomplished this in record time.' New York State inspectors examined laboratory staff qualifications, equipment, facilities, safety program, record, and overall management to ensure the highest standard of care for all laboratory patients. This license follows the College of American Pathologists (CAP) accreditation Artera received in August and the State of California license in October of last year. Together, these certifications underscore Artera's commitment to quality and patient safety. 'We are thrilled that the ArteraAI Prostate Test is now available in New York,' said Himanshu Nagar, MD, Director of Genitourinary Cancer, Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. 'This test complements existing biomarkers by integrating multimodal AI analysis of both digital pathology and clinical data, providing an additional layer of precision in risk stratification. By leveraging AI-driven insights, it enhances our ability to personalize treatment decisions, ensuring that patients receive the most appropriate therapy while minimizing unnecessary interventions.' About Artera Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials. Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at
Business Wire
an hour ago
- Business Wire
Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer. Additionally, the study will monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera's commitment to advancing personalized cancer treatment and identifying future opportunities for test optimization. The DIRECT-AI study centers on the award-winning ArteraAI Prostate Test—the only test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for localized prostate cancer that can both predict therapy benefit and prognosticate long-term outcomes. "Harnessing the power of AI, the ArteraAI Prostate Test marks a significant advancement in the personalized treatment of localized prostate cancer. Through the DIRECT-AI registry, we are rigorously evaluating how this technology can enhance clinical decision-making and improve patient outcomes, providing clinicians and patients with the most accurate, tailored insights available," said Dr. Tim Showalter, Chief Medical Officer at Artera. The study is structured into two phases. The initial phase captures real-world insights into how the Artera Prostate Test informs clinical decision-making, with feedback collected from participating clinicians and patients. The second phase will monitor long-term health outcomes at key intervals of 2 and 5 years, looking at endpoints such as distant metastasis, survival rates, and treatment effectiveness. This research will help Artera understand how its test impacts cancer outcomes and monitor its performance so that it can be improved for patients in the future. Any patient receiving the commercial ArteraAI Prostate Test and whose ordering physician is associated with an enrolling clinic is eligible to participate in the study. Patients must have localized prostate cancer and must not have started or received treatment for their condition. The study is non-interventional, meaning it does not require additional procedures or tests, and there will be no changes to the care participants receive, regardless of their participation. For clinics participating in the DIRECT-AI Registry, physicians can enroll all patients for whom they order an ArteraAI Prostate Test in the study. For more information and to sign up, visit the website or contact direct-ai@ About Artera Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials. Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at
USA Today
an hour ago
- USA Today
Salmonella outbreak tied to pistachio cream: See where people got sick
Salmonella outbreak tied to pistachio cream: See where people got sick Show Caption Hide Caption Tips to help manage food recalls and prevent foodborne illnesses About 128,000 are hospitalized and 3,000 people die each year from preventable foodborne illnesses. Payton, USA TODAY Tubs of pistachio cream are being recalled after nearly half a dozen people reported becoming ill with salmonella infections, according to the Food and Drug Administration (FDA). Emek-brand Pistachio Cream — a product sold online for wholesale distributors, restaurants, and food service locations across the country — has been linked to a salmonella outbreak in at least two states, the FDA said. The product, a nut butter spread used in desserts, including ice cream, is manufactured by Emek Dogal Saglik Urunleri Iklim Gida Insaat San Tic Ltd Sti in Turkey and imported into the United States. The FDA and the Centers for Disease Control and Prevention (CDC), in collaboration with state and local partners, are investigating the multistate outbreak. As of May 19, four people, three of them in one north central state, reported becoming ill after eating the affected product, the FDA wrote in its updated June 13 post. The FDA said it is also working to determine whether "other lots or products from this firm may be impacted." Here's what to know about the cream recall: Tomato recall: Vegetable sold in 3 states now labeled deadly by FDA What states were people sickened by recalled pistachio cream? So far, people in two states have reported being sickened from the product, according to the FDA and the CDA. Minnesota (three people) New Jersey (one person) What pistachio cream is being recalled? The FDA is recalling some Emek-brand Pistachio Cream packaged in a 5-kilogram white tub. The recalled cream has a use-by date of Oct. 9, 2026, and the production code (PNO:) of 241019. How many were sickened from recalled pistachio cream? According to its online post, the FDA was notified by the Minnesota Department of Health about "a cluster of Salmonella illnesses and two Salmonella positive samples of Emek-brand Pistachio Cream product that matched clinical cases by whole genome sequencing (WGS) in this outbreak." As of June 13, four cases of salmonella infection had been reported from two states. Of those cases, all four reported eating pistachio cream, the FDA said, and three of the four cases reported eating pistachio cream at the same restaurant. One of the individuals who consumed the affected cream had to be hospitalized, the FDA said. What is salmonella? Salmonella is an organism that can cause serious and fatal infections in children, the elderly and others with weakened immune systems, according to the CDC. Most people infected with salmonella start developing symptoms 12 to 72 hours after eating the contaminated product. Diarrhea, fever and abdominal cramps are the main symptoms. Most people recover without treatment, but in rare circumstances, the infection can require hospitalization, according to the CDC. Pregnant women are also at higher risk of developing an infection from it and should seek medical attention if symptoms arise. Consumers experiencing an illness because of the affected product should contact their health care provider to report their symptoms and for medical care. Natalie Neysa Alund is a senior reporter for USA TODAY. Reach her at nalund@ and follow her on X @nataliealund.
